Pancreatic Cancer Research

ReviewBiotechnol Bioeng2021

Nonviral siRNA delivery systems for pancreatic cancer therapy.

Journal
Biotechnol Bioeng
Published
8 July 2021
Citations
14
Type
Review

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)-based therapeutics. Recent advances in drug delivery systems hold great promise for improving siRNA-based therapeutics and developing a new class of drugs, known as nano-siRNA drugs. … Excerpt only: this text is the publisher’s. Read it in full at the source.